Neo Ivy Capital Management

Position in TGTX — Tg Therapeutics, Inc.

CIK 1727783 NEW YORK, NY

Position in TGTX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$2,020,872

+$1,753,143 QoQ

Shares Held

60,833

+795.9% QoQ

Ownership

0.040%

of shares outstanding

% of Portfolio

0.54%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2020

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Neo Ivy Capital Management holds $22,354,354 across 16 Biotechnology names. TGTX ranks #5 (9.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	DYN	Dyne Therapeutics, Inc.	168,753	$3,059,491
2	FOLD	AMICUS THERAPEUTICS, INC.	186,172	$2,692,047
3	BMRN	Biomarin Pharmaceutical Inc	43,355	$2,449,123
4	KYMR	Kymera Therapeutics, Inc.	27,033	$2,251,578
5	TGTX	Tg Therapeutics, Inc. This page	60,833	$2,020,872
6	ADMA	Adma Biologics, Inc.	199,687	$1,799,179
7	ROIV	Roivant Sciences Ltd.	64,106	$1,775,736
8	RARE	Ultragenyx Pharmaceutical Inc.	73,601	$1,541,940

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,020,872	60,833	+795.9%	Shares	Sole	2026-05-15
2025-03-31	$267,729	6,790	-93.3%	Shares	Sole	2025-05-06
2024-09-30	$2,357,244	100,780	+567.5%	Shares	Sole	2024-11-18
2023-06-30	$375,059	15,099	+189.9%	Shares	Sole	2023-08-16
2021-09-30	$173,355	5,209	-32.4%	Shares	Sole	2021-11-16
2021-06-30	$298,838	7,704	+272.4%	Shares	Sole	2021-08-16
2021-03-31	$99,725	2,069	-16.8%	Shares	Sole	2021-10-07
2020-12-31	$129,373	2,487	-52.2%	Shares	Sole	2021-02-16
2020-09-30	$139,366	5,208	-0.0%	Shares	Sole	2020-11-17
2020-06-30	$101,471	5,209	—	Shares	Sole	2020-08-17
No filing history on record for this holder in this stock.